Rexmyelocel T - Ixaka
Alternative Names: BM-MNCs - Ixaka; Bone marrow-derived mononuclear cells - Ixaka; REX-001Latest Information Update: 21 May 2021
At a glance
- Originator Rexgenero
- Developer Ixaka
- Class Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Peripheral ischaemia
Most Recent Events
- 21 May 2021 Rexgenero initiates enrolment in a phase III clinical trials in Peripheral ischaemia in Netherlands and Czech Republic (Intra-arterial) (NCT03111238) (EudraCT2016-000240-34)
- 31 Mar 2021 Rexgenero terminates a phase III clinical trials in Peripheral ischaemia in Austria, Hungary, Poland, Portugal, Netherlands, Germany, Czech Republic and Spain Republic (Intra-arterial) (NCT03111238)
- 18 Jan 2021 Rexgenero is now called Ixaka